agalsidase alfa Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
enzymes 5021 None

Description:

MoleculeDescription

Synonyms:

  • agalsidase alfa
  • replagal
  • agalsidase alfa (genetical recombination)
genetically engineered, glycosylated human alpha-galactosidase isoenzyme A used in treatment of Fabry disease
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
1 mg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Aug. 3, 2001 EMA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
ATC A16AB03 ALIMENTARY TRACT AND METABOLISM
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
Enzymes

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Fabry's disease indication 16652001 DOID:14499

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
globotriaosylceramide (GL-3) Metabolite HYDROLYTIC ENZYME DRUG LABEL DRUG LABEL

External reference:

IDSource
2HLC17MX9G UNII
D02784 KEGG_DRUG
104138-64-9 SECONDARY_CAS_RN
C0962517 UMLSCUI
CHEMBL2108214 ChEMBL_ID
DB15874 DRUGBANK_ID
8048 INN_ID
C000627036 MESH_SUPPLEMENTAL_RECORD_UI
008578 NDDF
423634009 SNOMEDCT_US
424905009 SNOMEDCT_US

Pharmaceutical products:

None